珍宝岛药业控股股东因债券换股被动减持，持股降至59.87%

Core Points - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. announced a notice regarding changes in the equity of its controlling shareholder [1] - From August 2 to September 18, the controlling shareholder, Chuangda Group, exchanged two tranches of convertible bonds for 9,223,963 shares, accounting for 0.98% of the total share capital [1] - As of September 18, a total of 16,550,986 shares have been exchanged, representing 1.76% of the total share capital [1] - Following this equity change, Chuangda Group's shareholding ratio decreased from 60.85% to 59.87%, crossing below the 60% threshold [1] - This change is a result of bondholders exercising their conversion rights, leading to a passive reduction in holdings, and does not trigger a mandatory tender offer or change the company's controlling shareholder or actual controller [1] - The company will continue to monitor the share conversion and disclose information in accordance with regulations, reminding investors to pay attention to risks [1]